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Abstract 
Description:  The purpose of this clinical practice update expert review is to describe the key 
principles in the use of surgical interventions and device-aided therapy for managing fecal 
incontinence (FI) and defecatory disorders.  
Methods:  The best practices outlined in this review are based on relevant publications, including 
systematic reviews and expert opinion (when applicable).   
Best practice advice 1:  A stepwise approach should be followed for management of FI. 
Conservative therapies (diet, fluids, techniques to improve evacuation, a bowel training program, 
management of diarrhea and constipation with diet and medications if necessary) will benefit 
approximately 25% of patients and should be tried first.   
Best practice advice 2:  Pelvic floor retraining with biofeedback therapy is recommended for 
patients with FI who do not respond to the conservative measures indicated above.  
Best practice advice 3:  Perianal bulking agents such as intraanal injection of dextranomer may 
be considered when conservative measures and biofeedback therapy fail. 
Best practice advice 4:  Sacral nerve stimulation should be considered for patients with moderate 
or severe FI in whom symptoms have not responded after a 3 month or longer trial of 
conservative measures and biofeedback therapy and who do not have contraindications to these 
procedures. 
Best practice advice 5:  Until further evidence is available, percutaneous tibial nerve stimulation 
should not be used for managing FI in clinical practice.  
Best practice advice 6:  Barrier devices should be offered to patients who have failed 
conservative or surgical therapy, or in those who have failed conservative therapy who do not 
want or are not eligible for more invasive interventions.  
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Best practice advice 7:  Anal sphincter repair (sphincteroplasty) should be considered in 
postpartum women with FI and in patients with recent sphincter injuries.  In patients who present 
later with symptoms of FI unresponsive to conservative and biofeedback therapy and evidence of 
sphincter damage, sphincteroplasty may be considered when perianal bulking injection and 
sacral nerve stimulation are not available or have proven unsuccessful. 
Best practice advice 8:  The artificial anal sphincter, dynamic graciloplasty, may be considered 
for patients with medically-refractory severe FI who have failed treatment or are not candidates 
for barrier devices, sacral nerve stimulation, perianal bulking injection, sphincteroplasty and a 
colostomy. 
Best practice advice 9:  Major anatomic defects (e.g., rectovaginal fistula, full thickness rectal 
prolapse, fistula in ano, or cloacalike deformity) should be rectified with surgery.  
Best practice advice 10:  A colostomy should be considered in patients with severe FI who have 
failed conservative treatment and have failed or are not candidates for barrier devices, minimally 
invasive surgical interventions, and sphincteroplasty. 
Best practice advice 11:  A magnetic anal sphincter device may be considered for patients with 
medically refractory severe FI who have failed or are not candidates for barrier devices, perianal 
bulking injection, sacral nerve stimulation, sphincteroplasty or a colostomy. Data regarding 
efficacy are limited and 40% of patients had moderate or severe complications.   
Best practice advice 12:  For defecatory disorders, biofeedback therapy is the treatment of 
choice. 
Best practice advice 13:  Based on limited evidence, sacral nerve stimulation should not be used 
for managing defecatory disorders in clinical practice. 
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Best practice advice 14:  Anterograde colonic enemas are not effective in the long-term for 
management of defecatory disorders.  
Best practice advice 15:  The STARR and related procedures should not be routinely performed 
for correction of structural abnormalities in patients with defecatory disorders.  
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Fecal Incontinence: Definition, Prevalence, and Impact on Quality of Life 
Fecal incontinence (FI) is the recurrent uncontrolled passage of liquid or solid stool.  FI 
affects 7 to 15% of community-dwelling women and men 1, 2.  The prevalence of FI is higher 
among care-seeking populations, home-care populations, and adults in long-term care settings 3.  
 FI can have a devastating impact on daily life 2, 4, 5, underscoring the need to manage the 
symptoms effectively.  In addition to a loss of confidence, self-respect, modesty, and composure 
6
, there is a social stigma attached to FI.  Thus, many people with FI do not share the condition 
with their friends or physicians.  Hence, physicians should routinely screen patients who may be 
at risk for symptoms of FI.  
 Having made the diagnosis of FI, the management is guided by the severity of FI, its 
impact on quality of life and the risk factors for FI.     
Symptom Severity and its Relationship with Quality of Life 
In clinical trials, severity is primarily evaluated by the frequency of FI using daily diaries; 
a 50% reduction in the number of episodes or days with FI is considered to be clinically 
significant improvement 7, 8.  Alternatively, the severity can be evaluated with questionnaire-
based instruments such as the Wexner and Modified Manchester Health Questionnaires, the 
Fecal Incontinence Severity Score, previously known as the Fecal Incontinence Constipation 
Assessment (FICA) FI symptom severity instrument and the Fecal Incontinence Severity Index 
(FISI) to name a few 9, 8.  All of the available instruments incorporate the frequency and type of 
leakage.  Some also incorporate the volume of leakage and rectal urgency, which contribute to 
the burden of FI.  So assessed, the severity of FI is strongly correlated with its impact on quality 
of life 5. 
Risk Factors for Fecal Incontinence 
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Patients with FI have anorectal dysfunctions and/or bowel disturbances, typically 
diarrhea.  In community surveys, bowel disturbances, particularly diarrhea, the symptom of 
rectal urgency, and burden of chronic illness rather than obstetric history (e.g., forceps use, 
complicated episiotomy) are by far the most important independent risk factors for FI in older 
women 9.  Specifically, in a community-based cohort of 176 randomly selected women with and 
176 without FI, independent risk factors for FI were diarrhea (odds ratio, OR=53 [95% CI=6.1–
471], cholecystectomy (OR=4.2 [95% CI=1.2–15]), current smoking (OR=4.7 [95% CI=1.4–15]), 
history of rectocele (OR=4.9 [95% CI=1.3–19]), stress urinary incontinence (OR=3.1 [95% 
CI=1.4–6.5]), and higher BMI (per unit increase, OR=1.1 [95% CI=1.004–1.1]) 10.  Other 
conditions associated with FI include advanced age, disease burden (co-morbidity count, 
diabetes), anal sphincter trauma (obstetrical injury, prior surgery), and decreased physical 
activity 9.  FI may be secondary to diseases that cause anorectal inflammation (e.g., inflammatory 
bowel disease), peripheral neuropathy (e.g., diabetes), iatrogenic anal sphincter injury, or 
neurological disorders (e.g., dementia, stroke, spinal cord injury or disease). 
Medical Management of FI 
Before considering surgical therapy or devices, all patients must be managed with 
conservative therapies that are tailored to the symptoms and rigorously implemented for an 
adequate duration.  These measures, which are detailed elsewhere, include dietary modification, 
fiber supplements, fluids, techniques to improve evacuation such as scheduled toileting, a bowel 
training program, pelvic floor exercises to strengthen musculature, and medications to manage 
diarrhea and constipation 7.  The next step is pelvic floor retraining with biofeedback therapy in 
which patients may work with their therapists using electronic and mechanical devices to 
improve pelvic floor strength, pelvic floor sensation and contraction, rectal sensation and 
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tolerance of rectal distention 11-13.  In our experience, many incontinent patients who are 
considered refractory to conservative therapy have, indeed, not received an optimal trial of 
conservative therapy, which includes one or more of the following measures as appropriate: (i) A 
meticulous characterization of the bowel habits, circumstances surrounding FI (e.g., relationship 
to meals and activity), and prior treatment for FI 14, (ii) Among patients with diarrhea, a careful 
dietary history to identify ingestion of poorly absorbed sugars (e.g., sorbitol, fructose) and/or 
caffeine followed by a trial of elimination, (iii) For diarrhea, we recommend starting with 
loperamide (2 mg) generally starting with 1 tablet taken 30 minutes before breakfast and titrated 
as necessary up to 16 mg daily. Fiber supplementation can be used to improve stool consistency 
and reduced diarrhea-associated FI 15. Because bile-salt malabsorption is common in patients 
with idiopathic diarrhea, cholestyramine or colesevelam may be helpful. Anticholinergic agents 
and clonidine 16 are alternative options for patients with diarrhea and FI. (iv) Laxatives and 
anorectal testing to identify evacuation disorders are recommended for patients with constipation 
17
. In particular, patients with fecal seepage suffer from evacuation disorders with overflow of 
retained stool in the rectum 18.  These conditions can be effectively managed with pelvic floor 
biofeedback therapy directed at addressing the underlying rectal evacuation disorder.  
Alternatively or in addition, rectal cleansing with a small enema or tap water reduces the 
likelihood of stool leakage.  Patients who are truly refractory to conservative measures should 
undergo anorectal testing, starting with anorectal manometry, followed if necessary by anorectal 
imaging (Figures 1 and 2) 19, 20.  These patients are eligible for surgical therapy or devices. 
Anorectal testing  
 Anal manometry is a simple test that can identify several anorectal dysfunctions (i.e., anal 
weakness, reduced or increased rectal sensation, and impaired rectal balloon expulsion) which 
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are associated with FI and amenable to pelvic floor biofeedback therapy 19.  Anal imaging with 
ultrasound or MRI can identify anal sphincter defects, atrophy, and a patulous anal canal 19, 21, 22.  
Imaging should be considered, in particular prior to surgery or devices.  It is easier to visualize 
internal sphincter tears with endoanal ultrasound than MRI 22.  By contrast, MRI is superior for 
visualizing external sphincter defects and atrophy and a patulous anal canal 19, 21, 22.   
Perianal bulking injection 
Perianal injection of biocompatible bulking agents is used to treat FI.  Dextranomer 
microspheres in non-animal stabilized hyaluronic acid (NASHA Dx) is the only Food and Drug 
Administration (FDA)-approved product for FI 23.  While the implied mechanism of action is to 
enhance the seal of the anal canal, dextranomer did not significantly increase anal resting or 
squeeze pressures nor was it superior to biofeedback therapy 24.  In a randomized, double-blind 
sham-controlled study in adults who had failed conservative therapies, 71/136 (52%) patients in 
the active treatment group vs. 22/70 (31%) in the sham group had a treatment response (≥50% 
improvement from baseline in the number of FI episodes) at 6 months (OR: 2.36; P = 0.0089) 25 
(Table 1).  A second injection was given to 112 (82%) patients in the NASHA Dx group, and a 
sham injection in 61 (87%) patients in the sham group.  At 6 months, compared with the sham 
group, patients in the NASHA Dx group had significantly more incontinence-free days, and 
improved FIQOL coping, and behavior but not lifestyle, depression and self-perception, or 
embarrassment scores.  The most common adverse events with NASHA Dx were proctalgia 
(14%), fever (8%), and rectal bleeding (7%); no apparent migration, protrusion, or leakage of 
NASHA Dx was observed during bowel movements.  At 12 and 24 months, 64.0% of 86 patients 
and 62.7% of 83 patients were responders in the NASHA Dx and sham groups, respectively 
(≥50% improvement from baseline in number of FI episodes) 26.  
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Sacral nerve stimulation for FI  
Sacral nerve stimulation (SNS) involves continuous pulsed electrical stimulation of the 
sacral nerves with a battery-operated stimulator.  Initially, stimulation is provided by an external 
electrical stimulator for 2-3 weeks.  If the frequency of FI declines by 50% or more, stimulator is 
permanently implanted beneath the skin.  
In the pivotal, uncontrolled, US multicenter trial, 90% of 133 patients proceeded from 
temporary to permanent stimulation27.  Among 76 of 120 patients (63%) with 5-year follow up 
data, 36% reported complete continence, and 89% were deemed a therapeutic success28.  There 
are few controlled studies.  Two parallel-group RCTs compared SNS to medical treatment and 
percutaneous tibial nerve stimulation (PTNS).29, 30 (Table 1).  In these studies, SNS was 
significantly better than medical treatment but not significantly better than PTNS.   
Most trials were limited to patients with a structurally intact anal sphincter or a defect 
smaller than 120°. Although a few studies have suggested that SNS may be beneficial 
irrespective of the degree of sphincter injury 31, 32, larger prospective trials are needed to confirm 
these findings.  Hence, the efficacy of SNS in patients with larger external sphincter defects is 
unknown.  Batteries must be replaced after approximately 7 years.  The most common adverse 
events are pain and infection at the insertion site which occurs in up to 10% of patients 27.  These 
data suggest that SNS is an effective surgical option for selected patients with FI.   
In six crossover studies of SNS for FI, patients experienced equal symptoms with the 
stimulator on or off 33.  The discrepancy between symptom-improvement and relatively minor 
effects on anorectal functions is puzzling 34.  Perhaps improved continence is explained by SNS-
induced colonic retrograde propagated sequences, which may be anticipated to delay colonic 
transit 35.  
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Percutaneous tibial nerve stimulation 
The posterior tibial nerve can be stimulated via a skin-surface electrode (transcutaneous 
stimulation) or a needle (percutaneous tibial nerve stimulation, PTNS).  In, predominantly 
uncontrolled, studies, 52% to 82% of patients reported a 50% or greater reduction in frequency 
of FI with PTNS 36.  In a small randomized trial of 30 patients with FI, a 50% or greater 
reduction in FI episodes was observed in 9 of 11 patients (82%) with percutaneous, 5 of 11 
(45%) with transcutaneous, and 1 of 8 (13%) with sham transcutaneous stimulation 37.  
Thereafter, a large, multicenter RCT observed that transcutaneous stimulation was not 
significantly better than sham stimulation, provided by a needle inserted to 2 mm but no 
electrical stimulation 36.  However, during that study, loperamide use was reduced by 29% of 
patients on PTNS but only 11% in the placebo group; differences were not significant (p=0.06). 
Barrier devices for FI 
A Cochrane review identified four randomized crossover or parallel studies of anal plugs 
or barrier devices, none of which are available in the United States.  This review observed that 
while anal plugs might be helpful in some patients, they are poorly tolerated, with a dropout rate 
ranging from 12.5% to 68% across the four studies 38. More recently, a new anal insert device 
(Renew Medical Inc., Foster City, CA), which is designed to be better tolerated than other plugs 
has become approved by the Food and Drug Administration in the United States.  In an open 
label study, 62% of patients reported a 50% or greater reduction in FI frequency; 78% of users 
were extremely satisfied with the device.  There were no serious adverse events and only three 
moderate adverse events (i.e., fecal urgency, soreness, and bleeding hemorrhoids) 39.  Another 
device, a vaginal insert and pressure-regulated pump was also assessed in a prospective open-
label study in women with FI.  Of 110 participants, 61 completed successful fitting of the device 
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of whom 78.7% achieved treatment success, defined as  > 50% reduction of incontinent episodes 
at 1 month 40.  Secondary analysis of bowel function also showed reduction in stool frequency, 
urgency, liquid stool and incomplete evacuations 41.  Additional randomized studies of longer 
duration will be needed to fully assess the utility of novel barrier devices, as they may be an 
effective treatment option for patients who fail standard conservative or surgical therapy. 
Anal sphincteroplasty    
Sphincteroplasty for surgical repair of anal sphincter defects may be performed using an 
“end-to-end” repair or an “overlap” repair. Post-operative complication rates are generally low.  
Rates for the most commonly reported complication of wound infection range from 6 to 35% 42.  
Success rates decline with time after the procedure.  For example, only 28% were continent at 40 
months in one study 43 and predicted median time to relapse of FI after sphincteroplasty is five 
years 44.  Given these data, anal sphincteroplasty is primarily reserved for women with 
postpartum FI.  Technical and patient-related factors influencing prognosis after sphincteroplasty 
are not clearly established.  Age, gender, extent of sphincter injury, etiology of sphincter injury, 
duration of FI, presence or absence of pudendal neuropathy, and surgical technique have all been 
considered as potential factors.  However, none of these factors has consistently demonstrated a 
clear correlation with outcomes 45,46, 47.   There is also little data comparing sphincteroplasty to 
newer approaches such as SNS, though one retrospective comparison of sphincteroplasty to SNS 
did not clearly demonstrate superiority of either intervention 32.  Given these limitations, newer 
modalities with minimally invasive approaches may soon be considered the preferred first-line 
surgical approach to treatment of FI except in those with recent or acute sphincter injuries. 
Artificial bowel sphincter (ABS) and dynamic graciloplasty for FI 
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ABS is comprised of an inflatable cuff that acts as a new sphincter, a control pump, and a 
balloon that regulates the pressure and also acts as a fluid reservoir 48.  The inflated cuff helps to 
maintain continence, and the deflated cuff facilitates evacuation.  Comparisons of its efficacy are 
confounded by the different scales used to define improvement 23.  The largest single-center 
study published (n = 52 patients and 85 devices; mean follow-up, >5 years) showed that full 
continence is seldom achieved, 14% had device-related infections and 32% required explantation 
48
.  Others have reported higher rates of complications and explantations 23.   
 
 
Graciloplasty uses the patient’s gracilis muscle to encircle the anus and form a new 
sphincter.  Dynamic graciloplasty consists of implanting an electrical stimulator in the abdominal 
wall to sustain the tone of the graciloplasty and thereby maintain continence.49  In a multicenter 
international trial of dynamic graciloplasty, success, defined as a ≥50% reduction in incontinent 
episodes, was reported in 47 of 76 (62%), 37 of 67 (55%), and 35 of 62 (56%) patients at 12 
months, 18 months, and 2 years post-treatment, respectively 49.  A systematic review reported 
dynamic graciloplasty success rates of 42 % to 85%, with the most common AEs being infection 
(28%), stimulator malfunction (15%), and leg pain (13%) 50.  Very few reports and no clinical 
trials of this procedure have been published during the last few years, suggesting that treatment is 
not routinely performed.  
Secca  
This procedure involves delivering temperature-controlled radiofrequency energy (465 
kHz, 2-5 W) to the anorectal junction with a goal of remodeling, scarring and causing 
contraction of the collagen tissues in anal region.  Manometry and endoanal ultrasound tests did 
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not reveal any changes 51.  In a 5-year follow-up of 19 patients, sustained improvements in FI 
symptoms and FIQOL were reported when compared to baseline 52.  Other studies have also 
reported modest improvements in one or both of these measures, albeit over a shorter time 
duration 53-55.  In a review of 10 Secca studies comprising 220 patients, FI improved in 55 to 
80% of patients,; complications occurred in 20% of patients.  Most studies included small 
numbers of patients and most were conducted over 8 years ago.  There are no randomized 
controlled trials, but it has been FDA-approved since 2002 for patients who have failed 
conservative therapy for FI.   
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Colostomy 
 Fecal diversion through creation of a colostomy or ileostomy offers definitive therapy for 
FI in patients who have failed or are not suitable for standard conservative of surgical treatments.  
Despite its curative potential, colostomy is not commonly used due to concerns for poor quality 
of life, particularly in the domains of psychologic and social function 56, 57.  However, in one 
cross-sectional survey study 58 patients with colostomy formation reported higher social function 
scores on the SF-36 as well as higher coping, embarrassment, lifestyle and depression scores on 
the FIQOL compared to patients with FI.  Another survey found 84% of patients who had a 
colostomy for FI would choose to have it again 59.  However, generalizability of these findings 
may be limited due to patient selection.  Mortality rates for colostomy are approximately 2% 50 
and associated complications may include bleeding, cardiopulmonary events related to 
anesthesia, and parastomal hernia 23.  Major long-term stomal problems may also include rashes, 
leakage and ballooning 60.  
Magnetic anal sphincter 
The magnetic anal sphincter comprises a series of interlinked titanium beads with internal 
magnetic cores that form a flexible ring, encircling the EAS and creating a barrier.  During 
defecation, the beads separate, allowing stool to pass.  In a prospective, non-randomized matched 
study (n = 20) FI severity and FIQOL scores improved significantly after implantation of a 
magnetic or artificial anal sphincter 61.  No significant differences in early postoperative 
complications were observed, but surgical time (62 vs. 97 min) and hospital stay (4.5 versus 10 
days) were shorter for the magnetic sphincter group than the artificial sphincter group.  The 
device is approved in several European countries (e.g., United Kingdom and France) and, 
through the humanitarian device exemption (HDE) process, by the United States FDA agency.  
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The FDA approval, which is based on a report of 35 patients, is for patients with FI “who are not 
candidates for or have previously failed conservative treatment and less invasive therapy options 
(e.g., injectable bulking agents, radiofrequency ablation, sacral nerve stimulation) 62.”  This 
approval considered a dataset in which all patients had completed follow up at 36 months with 
partial follow up at 48 and 60 months. At 36 months, 57% of patients reported a ≥ 50% reduction 
in FI episodes.  Seven patients (20%) had the device explanted for infection, erosion, or lack of 
effect and another patient required a stoma for relieve obstructed defecation.  Including other 
complications (e.g., pain and bleeding), 40% of patients had moderate or severe complications.      
Costs of treatment 
 The costs of conservative treatment in 2010 dollars adjusted for 2013 dollars was $2584 
($2067 - $3101) 63.  For other treatments, the costs in 2013 dollars are as follows 63.  For 
biofeedback therapy, the cost for a 3 month trial was $796 ($638 – $955).  Dextranomer, mean 
(range) physician and procedure costs were $5181 ($3165 – $7197).  For SNS, corresponding 
figures were $35,818 ($28,654 – $42,982).   
Defecatory Disorders  
Defecatory disorders (DD) are defined by symptoms of chronic constipation or 
constipation-predominant IBS associated with anorectal tests indicative of impaired rectal 
evacuation. 20  These disorders are common in the community with a prevalence of 22 [versus 
5.8 for Crohn’s disease] per 100,000 person years 64.  In patients with chronic constipation 
unresponsive to laxatives, anorectal testing is necessary to identify DD 17, 65.  Dyssynergic 
defecation should be managed by biofeedback therapy, which is not widely available 66.  When 
patients do not respond to an adequate trial of pelvic floor retraining with biofeedback therapy, 
options include: (i) ongoing medical management with an emphasis on suppositories and enemas, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
 
(ii) evaluation for pelvic floor structural abnormalities (e.g., clinically significant rectoceles or 
enteroceles) with appropriate surgical management for the same, (iii) management of colonic 
motor dysfunction (e.g., prokinetic agents), and (iv) surgery or devices for defecatory disorders.  
This category includes anal sphincter injection of botulinum toxin, sacral nerve stimulation, and 
the STARR procedure.  
Sacral nerve stimulation (SNS) for defecatory disorders 
 In addition to several retrospective reports 67, three prospective studies have evaluated 
SNS for chronic constipation.  In a multicenter European trial published in 2010, 45 of 62 
patients with constipation refractory to medical management proceeded from temporary to 
permanent SNS 68.  Of 62 patients, 81% had slow colon transit and 18% had “normal transit 
constipation with impaired evacuation”.  Bowel symptoms (frequency, straining, and incomplete 
evacuation) and QOL improved significantly after a median follow up of 28 months (range 1-55 
months).  The effects of SNS on colonic transit and rectal evacuation were only evaluated in a 
subset of patients; some parameters improved.  By contrast, in a prospective, 18-week 
randomized, double-blind, placebo-controlled, two-phase crossover study, neither sub- nor 
supra-sensory SNS increased the proportion of complete bowel movements compared to sham 
SNS in 55 patients with medically-refractory slow transit constipation and normal anorectal 
functions evaluated with manometry, rectal balloon expulsion, and proctography 69.  Hence, 
although small studies suggest that SNS may improve rectal sensation in patients with DD and 
rectal hyposensitivity 70  and induce colonic propagating sequences71, there is no evidence that 
SNS improves bowel symptoms or rectal evacuation in defecatory disorders.  
Anterograde colonic enema procedures for defecatory disorders 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
 
Malone described a surgically-created appendicostomy for delivering anterograde colonic 
enemas in children with constipation or FI 72.  In adults, where the appendix is not always 
available or stenosed, Malone anterograde continence enemas have been used in patients with 
medically-refractory severe DD 73.  This report provided follow up data in 17 of 20 patients; 13 
patients were satisfied with the outcome; the outcome of two patients was unchanged and one 
patient was worse.  Enemas can be delivered via a button cecostomy device created by a 
colonoscopy and percutaneous technique 73, 74.  In these small series, follow up was short, and 
success rates were lower in adults (approximately 50%) than children (80%).  Long-term 
complications such as stoma stenosis or leakage, or failure to effectively treat symptoms 
commonly (> 50% at 3 years) require revision, reversal or conversion to a formal stoma 74.  
Moreover, this procedure does not address the primary dysfunction, i.e., pelvic floor dysfunction.  
Hence, in our opinion, this is not an effective long term solution for adults with DD.   
Stapled transanal rectal resection and ventral rectopexy for DD 
 Some patients with DD may have rectoceles and/or rectal intussusception (occult rectal 
prolapse).  Because these structural abnormalities may at least partly result from excessive 
straining and/or pelvic floor dysfunction, they are primarily managed with pelvic floor 
biofeedback therapy.  Surgical options, which can be transanal (STARR and Contour transtar) 
or transabdominal approaches (i.e., ventral rectopexy) are considered for clinically significant 
rectoceles (e.g., large defects, those that fill preferentially and/or fail to empty on a defecating 
proctogram) and symptomatic rectoceles (e.g., when patients recourse to vaginal stenting during 
defecation).   
 These procedures aim to cure symptoms by excluding the redundant rectal mucosa 
associated with a rectocele and intussusception.  A prospective, multicenter trial randomized 119 
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patients with rectal intussusception or a rectocele, size not specified, to STARR or biofeedback 
therapy 75 (Table 1).  It is unclear how many, if any, patients had impaired rectal evacuation at 
baseline.  Thirteen patients withdrew before treatment.  At one year, 44 of 54 (82%) STARR 
patients versus 13 of 39 (33%) biofeedback patients reported a greater than 50% reduction in the 
obstructed defecation scores; 25% of biofeedback patients (13/52) withdrew before the end of 
treatment.  The constipation-related QOL also improved significantly in both groups.  However, 
8 (15%) STARR patients had adverse events (i.e., infection, pain, incontinence, bleeding, UTI, 
or depression), occasionally severe and requiring further surgery, while only one biofeedback 
patient experienced anal pain.  Other complications after STARR procedure include fistula, 
peritonitis, and bowel perforation 76-78.  
 The correlation between symptoms and rectocele size is weak 79.  The correlation between 
improvement in symptoms and anatomy after the STARR procedure is also weak; symptoms 
may improve despite modest effects on anatomic disturbances 78, 80, 81 and vice versa 82.  It is 
quite probable that anatomic abnormalities, such as intussusception and complete rectal prolapse, 
are actually caused by the underlying disorder of function (impaired pelvic floor relaxation and 
excessive straining), which is not corrected by the procedure.  Finally, the long-term outcomes of 
patients even ideally suited for STARR are somewhat disappointing 83.  The operation has failed 
to gain widespread acceptance in the United States.   
Surgery for rectal prolapse 
 Asymptomatic Grade 1-2 rectal prolapse does not require surgery, and should be managed 
with conservative and/or biofeedback therapy to correct underlying dyssynergia.  However, in 
addition to these measures, patients with symptomatic grade 3-4 prolapse require surgery, using 
either an abdominal approach (i.e., resection, rectopexy, or both) or perineal resection. A 
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Cochrane review that included 12 randomized trials with 380 patients concluded that “there is 
insufficient data to say which of the abdominal and perineal approaches has a better outcome.  
Division, rather than preservation, of the lateral ligaments was associated with less recurrent 
prolapse but more postoperative constipation.  Laparoscopic rectopexy was associated with 
fewer post-operative complications and shorter hospital stay than open rectopexy.  Bowel 
resection during rectopexy was associated with lower rates of constipation 84.”  However, bowel 
resection should be avoided in patients with preexisting diarrhea and/or incontinence as these 
symptoms may worsen with resection.  
 In practice, the perineal approach is more frequently used in clinical practice, has lower 
perioperative morbidity, and a higher recurrence rate.  In general, elderly patients, those with 
significant medical comorbidities, or those with contraindications for abdominal surgery are 
often the best candidates for a perineal procedure, generally a perineal proctosigmoidectomy 
(Altemeier procedure) 85.  This may be combined with transperineal levatoroplasty which may 
help to reduce the risk of recurrence 86.   
Recurrence rates for transabdominal rectopexy are low (0–8%); however, after posterior 
rectopexy 50% of patients complain of severe constipation 87, 88.  Perineal procedures have a 
recurrence rate of 5-21% with similar incidence of constipation 88.  
   Pouch of Douglas protrusion, which is often confused with rectal intussusception and full-
thickness rectal prolapse, is best addressed with sacrocolpopexy and is usually performed in 
conjunction with other gynecologic procedures in patients with pelvic floor abnormalities such as 
cystoceles, rectoceles, and enteroceles and vaginal vault prolapse. 
Conclusions   
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 Surgical options may be considered in patients with FI and DD who have failed 
conservative therapy.  Our experience suggests that many patients undergo surgical therapy 
without a rigorous trial of conservative therapy (e.g., biofeedback therapy for DD or antidiarrheal 
agents in patients with diarrhea and FI).  Among surgical procedures, sacral nerve stimulation is 
a safe and effective option for FI.  There is less evidence to support the routine use of other 
surgical procedures sans a colonic stoma for FI.  For some emerging surgical options (e.g., 
magnetic anal sphincter), limited evidence suggests modest efficacy and the potential for severe 
side effects.  In our experience, surgery is necessary in a very small fraction, perhaps < 5% of 
patients with DD, generally patients with considerable pelvic organ and/or rectal prolapse.  There 
is a critical need for clinical trials comparing various surgical procedures and conservative with 
surgical therapies.    
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Figure Legends 
Figure 1.  Algorithm for the diagnosis and management of fecal incontinence. 
Figure 2. Surgical Devices and Procedures for Managing Fecal Incontinence 
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Table 1. Systematic Review of Randomized Controlled Trials of Surgery or Devices for Fecal Incontinence and Defecatory 
Disordersa 
Author Year, Countries Study Design Treatments (n) Findings b 
FI     
Tjandra 29 2008, Australia Parallel-group RCT SNS (60) and medical 
treatment (60) 
At 12 months, a ≥ 50% reduction in FI frequency 
observed in 71% of 53 patients receiving 
permanent SNS (data not provided for medical 
treatment). Episodes of incontinence were 
significantly lower at 12 months with SNS than 
with medical treatment (MD −6.30, 95% CI 
−10.34 to −2.26) 
Thin 30 2015, United 
Kingdom 
Investigator-blinded 
parallel-group RCT 
SNS (23) and PTNS (17) At 6 months, a ≥ 50% reduction in FI frequency 
observed with SNS (11 of 18, 61%) and PTNS (7 
of 15, 47%); differences were not significant  
George 37 2013, United 
Kingdom 
Single-blind, parallel-group, 
RCT 
PTNS (11), 
Transcutaneous (11), Sham 
At 6 weeks, a ≥ 50% reduction in FI frequency 
was significantly greater for PTNS (82%) than 
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(8) stimulation transcutaneous (45%) or sham (13%) stimulation. 
Improvements were maintained over 6 months. 
Knowles 36 2015, United 
Kingdom 
Double-blind, multicenter, 
pragmatic, parallel-group, 
RCT 
PTNS (115) or sham 
stimulation (112) of tibial 
nerve once per week for 12 
weeks 
For ≥ 50% reduction in FI frequency at 12 weeks, 
differences between PTNS (39 of 103, 38%) and 
sham (32 of 102, 31%) were not significant.  
Graf 25 2011, Multicenter 
(USA, Europe) 
Double-blind RCT Dextranomer (136) or 
sham (70) 
At 6 months, a ≥ 50% reduction in FI frequency 
was significantly greater for dextranomer (52%) 
than sham (31%) 
DD     
Lehur 75 2008, France, 
Italy, United 
Kingdom 
RCT STARR (54)  
Biofeedback (52) 
Bowel symptoms improved in 44 (82%) STARR 
vs. 13 (33%) evaluable biofeedback patients.  
RCT = randomized controlled trial 
a
 This Table does not include crossover studies 
b
 For proportions, the denominator is the number of patients for whom evaluable data were reported in the trial
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